NCT00380796 - A Long-term Safety Study of Infliximab in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD). | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions

COPDPulmonary Disease, Chronic Obstructive

Interventions

DRUG

Collection of safety data for Cohort 1

Twice-yearly collection of information about cancer incidence and cause of death among patients who participated in clinical trials of infliximab in the treatment of COPD. The follow-up period is 5 years.

Trial Locations (26)

Unknown

Anaheim

San Diego

Bay Pines

Clearwater

Blue Ridge

Baltimore

Springfield

Minneapolis

Saint Charles

St Louis

Omaha

Las Vegas

Lebanon

Endwell

Larchmont

Winston-Salem

Cincinnati

Easton

Hershey

Philadelphia

Greer

Spartanburg

Amarillo

Dallas

Salem

Madison